Market Watch: Mesoblast shares down 14%

By Tim Dean
Monday, 31 October, 2011

The share price of stem cell specialists Mesoblast (ASX:MSB) shed 14% of its value in trading on Friday and today, down from $9.39 at Thursday’s close of trading to $8.25 as of midday today.

The drop was precipitated by Macquarie Research updating its rating for the biotech to “underperform”.

Other analysts have recently rated Mesoblast as “buy”, with Nomura setting a target price of $10.15 and Bell Potter $16.00 both only one month ago.

Late last year Mesoblast wowed the industry with its monumental deal with Cephalon, and recently announced it was partnering with Lonza to manufacture it’s off-the-shelf mesenchymal precursor stem cells.

Follow this link for a detailed profile of Mesoblast and its technology, and an interview with its CEO, Professor Silviu Itescu.

Related News

Novel antibiotic activates 'suicide' mechanism in superbug

Researchers have discovered a new class of antibiotic that selectively targets Neisseria...

Modifications in the placenta linked to psychiatric disorders

Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...

ADHD may be linked with an increased risk of dementia

An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd